Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BRKR
stocks logo

BRKR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
958.80M
-2.12%
0.651
-14.38%
801.63M
+0.03%
0.420
-10.66%
817.97M
+2.58%
0.413
+28.94%
Estimates Revision
The market is revising Downward the revenue expectations for Bruker Corporation (BRKR) for FY2025, with the revenue forecasts being adjusted by -0.92% over the past three months. During the same period, the stock price has changed by 62.40%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.92%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.88%
In Past 3 Month
Stock Price
Go Up
up Image
+62.40%
In Past 3 Month
Wall Street analysts forecast BRKR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 44.60 USD with a low forecast of 42.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast BRKR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 44.60 USD with a low forecast of 42.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 48.380
sliders
Low
42.00
Averages
44.60
High
50.00
Current: 48.380
sliders
Low
42.00
Averages
44.60
High
50.00
Rothschild & Co Redburn
Buy
initiated
$60
2025-11-20
Reason
Rothschild & Co Redburn
Price Target
$60
2025-11-20
initiated
Buy
Reason
Rothschild & Co Redburn initiated coverage of Bruker with a Buy rating and $60 price target, representing 41% potential upside. Bruker has underperformed its life science equipment peers year-to-date, with revenue and margins pressured by academic and government budget cuts and tariffs, the analyst tells investors in a research note. However, the firm views the company as well positioned to return to above-market earnings growth from 2026, given its leadership in proteomics and demand for next-generation systems such as mass spectrometry.
UBS
Neutral
maintain
$40 -> $43
2025-11-04
Reason
UBS
Price Target
$40 -> $43
2025-11-04
maintain
Neutral
Reason
UBS raised the firm's price target on Bruker to $43 from $40 and keeps a Neutral rating on the shares. Despite the 2025 guidance cut, bookings are mostly "constructive," the analyst tells investors in a research note.
TD Cowen
Dan Brennan
Hold
maintain
$40 -> $42
2025-11-04
Reason
TD Cowen
Dan Brennan
Price Target
$40 -> $42
2025-11-04
maintain
Hold
Reason
TD Cowen analyst Dan Brennan raised the firm's price target on Bruker to $42 from $40 and keeps a Hold rating on the shares. The firm updated its model after posting an inline Q3 and reiterated guidance.
Barclays
Overweight
maintain
$40 -> $45
2025-11-04
Reason
Barclays
Price Target
$40 -> $45
2025-11-04
maintain
Overweight
Reason
Barclays raised the firm's price target on Bruker to $45 from $40 and keeps an Overweight rating on the shares post the Q3 report. The company's end markets remain relatively stable but soft, the analyst tells investors in a research note.
Nephron Research
Sell
to
Hold
upgrade
2025-11-03
Reason
Nephron Research
Price Target
2025-11-03
upgrade
Sell
to
Hold
Reason
Nephron Research upgraded Bruker to Hold from Sell.
Stifel
Daniel Arias
Hold
downgrade
$48 -> $40
2025-08-05
Reason
Stifel
Daniel Arias
Price Target
$48 -> $40
2025-08-05
downgrade
Hold
Reason
Stifel analyst Daniel Arias lowered the firm's price target on Bruker to $40 from $48 and keeps a Hold rating on the shares. The company's Q2 miss and revised outlook "featured a combination of both expected and unexpected factors," the analyst tells investors. The EPS guidance reset "should clear the deck on 2025 earnings," and "there will come a time again to own" the stock, but in the firm's view "we're not there yet," the analyst added.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bruker Corp (BRKR.O) is 23.91, compared to its 5-year average forward P/E of 26.73. For a more detailed relative valuation and DCF analysis to assess Bruker Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
26.73
Current PE
23.91
Overvalued PE
33.34
Undervalued PE
20.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
17.68
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
21.03
Undervalued EV/EBITDA
14.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.33
Current PS
0.00
Overvalued PS
4.31
Undervalued PS
2.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 113.25% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 113.25% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BRKR News & Events

Events Timeline

(ET)
2025-11-03
07:06:15
Bruker lowers FY25 EPS forecast to $1.85-$1.90, down from $1.95-$2.05; consensus remains at $1.94.
select
2025-11-03
07:03:18
Bruker announces Q3 earnings per share of 45 cents, surpassing consensus estimate of 33 cents.
select
2025-10-03 (ET)
2025-10-03
07:04:14
Bruker reveals new orders for cutting-edge nuclear magnetic resonance equipment
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-24Newsfilter
AST Revolution Acquired by Bruker, Advancing Rapid Antimicrobial Susceptibility Testing Technology
  • Acquisition Announcement: Indaba Capital announced the sale of AST Revolution to Bruker, with financial terms undisclosed, marking a strategic transformation for AST Revolution in the rapid antimicrobial susceptibility testing sector, which is expected to enhance its market competitiveness.
  • Technology Development: Established in August 2025, AST Revolution focuses on developing next-generation rapid antimicrobial susceptibility testing solutions aimed at improving patient outcomes and reducing healthcare costs, aligning with the urgent demand for efficient diagnostic tools in the healthcare industry.
  • Leadership and Support: With Indaba's backing, AST Revolution successfully advanced the product development of the WAVE™ and Arc™ systems, showcasing significant technological potential and positioning itself for leadership in the rapid AST market.
  • Team Collaboration: The management team of AST Revolution demonstrated exceptional collaboration during the acquisition process, ensuring operational stability and continuous technological advancement, laying the groundwork for this successful transaction.
[object Object]
Preview
6.0
11-21Benzinga
Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday

  • Analyst Upgrades: Several Wall Street analysts have upgraded their ratings on various companies, including AVITA Medical, Agios Pharmaceuticals, Nasdaq, Marsh & McLennan, and Parsons Corp.

  • AVITA Medical: BTIG analyst Ryan Zimmerman upgraded AVITA Medical from Sell to Neutral, with shares closing at $3.95.

  • Agios Pharmaceuticals: Leerink Partners analyst Andrew Berens upgraded Agios Pharmaceuticals from Market Perform to Outperform, lowering the price target from $40 to $34, with shares closing at $22.34.

  • Nasdaq and Marsh & McLennan: Morgan Stanley upgraded Nasdaq from Equal-Weight to Overweight, raising the price target from $97 to $110, while Barclays upgraded Marsh & McLennan from Equal-Weight to Overweight, lowering the price target from $221 to $206.

[object Object]
Preview
4.0
11-20Benzinga
Bellring Brands Analyst Changes Stance; Check Out Thursday's Top 3 Downgrades

  • Analyst Downgrades: TD Cowen downgraded Bellring Brands Inc from Buy to Hold, lowering the price target from $37 to $31, while Jefferies downgraded Globant SA from Buy to Hold with a price target cut from $80 to $61.

  • Semrush Rating Change: Jefferies also downgraded Semrush from Buy to Hold but raised the price target from $10 to $12.

  • Current Stock Prices: As of Wednesday, Bellring Brands shares closed at $29.26, Globant shares at $61.46, and Semrush shares at $11.76.

  • Market Overview: The article provides a snapshot of various stocks and their performance, indicating a mixed outlook from analysts on these companies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bruker Corp (BRKR) stock price today?

The current price of BRKR is 48.38 USD — it has increased 1.09 % in the last trading day.

arrow icon

What is Bruker Corp (BRKR)'s business?

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.

arrow icon

What is the price predicton of BRKR Stock?

Wall Street analysts forecast BRKR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 44.60 USD with a low forecast of 42.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bruker Corp (BRKR)'s revenue for the last quarter?

Bruker Corp revenue for the last quarter amounts to 860.50M USD, decreased -0.45 % YoY.

arrow icon

What is Bruker Corp (BRKR)'s earnings per share (EPS) for the last quarter?

Bruker Corp. EPS for the last quarter amounts to -0.41 USD, decreased -251.85 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bruker Corp (BRKR)'s fundamentals?

The market is revising Downward the revenue expectations for Bruker Corporation (BRKR) for FY2025, with the revenue forecasts being adjusted by -0.92% over the past three months. During the same period, the stock price has changed by 62.40%.
arrow icon

How many employees does Bruker Corp (BRKR). have?

Bruker Corp (BRKR) has 11396 emplpoyees as of December 05 2025.

arrow icon

What is Bruker Corp (BRKR) market cap?

Today BRKR has the market capitalization of 7.35B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free